<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> is one of the most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> worldwide and one of the leading causes of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-related <z:hpo ids='HP_0011420'>death</z:hpo> in the Western world </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">Tumor progression</z:e> towards <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> affects a large number of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and seriously affects their clinical outcome </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, considerable effort has been made towards the development of therapeutic strategies that can decrease or prevent <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Standard treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> with chemotherapy has been improved in the last 10 years by the addition of new targeted agents </plain></SENT>
<SENT sid="4" pm="."><plain>The currently used antibodies bevacizumab, cetuximab and panitumumab target the VEGF and EGFR signaling pathways, which are crucial for <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>These antibodies have shown relevant efficacy in both first- and second-line treatment of <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, other signaling pathways, including the Wnt and HGF/Met pathways, have a well-established role in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> progression and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> and constitute, therefore, promising targets for new therapeutic approaches </plain></SENT>
<SENT sid="7" pm="."><plain>Several new drugs targeting these pathways, including different antibodies and small-molecule <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi>, are currently being developed and tested in clinical trials </plain></SENT>
<SENT sid="8" pm="."><plain>In this review, we summarize the new developments in this field, focusing on the inhibitors that show more promising results for use in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
</text></document>